Dec 12, 2008
Before reading the information found below, please take note that if you are not yet using a mainstream MS medication and would like to enroll in an FTY720 clinical trial, contact your doctor to learn of a study location nearest you. OR, if in South Florida, Click HERE to see where you can enroll and/or obtain further information on FTY720..
Oral FTY720 (Fingolimod) Reduced Relapse Rate More Effectively Than Avonex in Initial Results of One-Year Study in Relapsing-Remitting MS
The experimental oral drug FTY720 (fingolimod, Novartis) reduced relapses significantly more than Avonex® (interferon beta-1a, Biogen Idec) in a one-year study involving 1,292 people with relapsing-remitting MS. Serious adverse events in the FTY720 group included two deaths from herpes infections and seven cases of localized skin cancer. These initial results are reported in a press release from Novartis, which notes that analysis of these data is ongoing and that two other large-scale, phase 3 trials of the drug are ongoing. The company expects to submit an application to the FDA for approval by the end of 2009.
Suggestions, Comments and/or Questions are always appreciated.. - Thank you